Clinical trials: Papillary Thyroid Carcinoma
Thyroid Neoplasms
Testicular Function After Iodine 131 Therapy in Papillary Carcinoma Patients
Papillary cancer may affect patients of any age,with a good prognosis. Most of young patients may hence procreate as often as the general population.131iodine is an essential tool during treatment of thyroid cancer.
- Trial name
- SAPIRA (NCT01150318)
- Testing
- Administration of 131 iodine
- Where
- France
- Volunteers
- 48 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Malignant Thyroid Gland Neoplasm, Poorly Differentiated Thyroid Gland Carcinoma
Selpercatinib Before Surgery for the Treatment of RET-Altered Thyroid Cancer
This phase II trial studies the effect of selpercatinib given before surgery in treating patients with thyroid cancer whose tumors have RET alterations (changes in the genetic material [deoxyribonucleic acid (DNA)]).
- Conditions
- Malignant Thyroid Gland Neoplasm, Poorly Differentiated Thyroid Gland Carcinoma, Recurrent Thyroid Gland Carcinoma, Thyroid Gland Anaplastic Carcinoma
- Trial name
- NCT04759911
- Testing
- Quality-of-Life Assessment, Questionnaire Administration, Selpercatinib
- Where
- 3 sites in United States
- Volunteers
- 30 people
- Sponsor
- M.D. Anderson Cancer Center
Medullary Thyroid Cancer, Infantile Myofibromatosis
A Study of Oral LOXO-292 (Selpercatinib) in Pediatric Participants With Advanced Solid or Primary Central Nervous System (CNS) Tumors
This is an open-label, multi-center Phase 1/2 study of oral LOXO-292 in pediatric participants with an activating rearranged during transfection (RET) alteration and an advanced solid or primary CNS tumor.
- Conditions
- Medullary Thyroid Cancer, Infantile Myofibromatosis, Infantile Fibrosarcoma, Papillary Thyroid Cancer
- Trial name
- LIBRETTO-121 (NCT03899792)
- Testing
- Selpercatinib
- Where
- 26 sites in United States, Australia and 9 more
- Volunteers
- 36 people
- Sponsor
- Eli Lilly and Company
Head and Neck Cancer
Gefitinib in Treating Patients With Locally Advanced or Metastatic Thyroid Cancer That Did Not Respond to Iodine Therapy
RATIONALE: Gefitinib may stop the growth of tumor cells by blocking the enzymes necessary for their growth. PURPOSE: Phase II trial to study the effectiveness of gefitinib in treating patients who have locally advanced or…
- Trial name
- NCT00095836
- Testing
- Gefitinib
- Where
- 2 sites in United States
- Volunteers
- 27 people
- Sponsor
- Massachusetts General Hospital
Papillary Thyroid Cancer, Follicular Thyroid Cancer
Sutent Adjunctive Treatment of Differentiated Thyroid Cancer
This study is comparing a drug called Sutent with standard of care treatment for people with advanced thyroid cancer. Because advanced thyroid cancer is becoming increasingly common and effective treatment options are limited…
- Conditions
- Papillary Thyroid Cancer, Follicular Thyroid Cancer, Differentiated Thyroid Cancer
- Trial name
- IIT Sutent (NCT00668811)
- Testing
- SU011248, Sutent
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- Medstar Health Research Institute
Papillary Thyroid Cancer
Definition of Mutational Profile of Papillary Thyroid Tumors by Mass-ARRAY
Somatic mutations in the MAP (mitogen-activated protein) kinase pathway have been found in about 80% of papillary thyroid tumors (PTCs).
- Trial name
- PTC-ARRAY (NCT05766098)
- Testing
- Genotyping
- Where
- Italy
- Volunteers
- 600 people
- Sponsor
- Istituto Auxologico Italiano
Papillary Thyroid Cancer
Overdiagnosis of Thyroid Cancer in the Marne and Ardennes Departments of France From 1975 to 2014
Introduction - Incidence of thyroid cancer has increased considerably in France in recent years, but the mortality rate has declined only slightly. Part of this increased incidence could be attributable to overdiagnosis.
- Trial name
- OTCancer (NCT03623516)
- Where
- France
- Volunteers
- 2,008 people
- Sponsor
- CHU de Reims
Non Small Cell Lung Cancer, Medullary Thyroid Cancer
Expanded Access for the Treatment of Cancers With Rearranged During Transfection (RET) Activation
Expanded access for participants with cancer with RET activation who are ineligible for an ongoing selpercatinib (also known as LOXO-292) clinical trial or have other considerations that prevent access to selpercatinib through an…
- Conditions
- Non Small Cell Lung Cancer, Medullary Thyroid Cancer, Colon Cancer, Breast Cancer
- Trial name
- NCT03906331
- Testing
- Selpercatinib
- Where
- 64 sites in United States, Australia and 11 more
- Sponsor
- Eli Lilly and Company
Thyroid Cancer, Recurrence
A Prospective, Open-label, Multicenter, Randomized Controlled Phase III Study of Prophylactic Central Neck Dissection in Low-risk Papillary Thyroid Cancer
papillary thyroid carcinoma (PTC) is the most common thyroid cancer and has a good prognosis. Surgery is the primary treatment for PTC, and occult lymph node metastasis is not uncommon (20%-80%).The lymph node metastasis of PTC…
- Trial name
- NCT06082180
- Testing
- prophylactic central neck dissection
- Where
- China
- Volunteers
- 1,199 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Thyroid Neoplasm, Lymphatic Metastasis
Prophylactic Selective Lateral Neck Dissection in Patients With Papillary Thyroid Carcinoma
The purpose of this study is to prospectively analyze the incidence of occult lateral neck metastasis (LNM) and to elucidate the factors that predict LNM in papillary thyroid carcinoma (PTC) with central neck metastasis (CNM) by…
- Trial name
- NCT01103557
- Testing
- prophylactic selective lateral neck dissection
- Volunteers
- 62 people, healthy volunteers welcome
- Sponsor
- Pusan National University Hospital
Solid Tumor and Hematologic Malignancies
MEK162 for Patients With RAS/RAF/MEK Activated Tumors
The purpose of this signal seeking study is to determine whether treatment with MEK162 demonstrates sufficient efficacy in select pathway-activated solid tumors and/or hematologic malignancies to warrant further study
- Trial name
- SIGNATURE (NCT01885195)
- Testing
- MEK162
- Where
- 68 sites in United States
- Volunteers
- 110 people
- Sponsor
- Pfizer
Head and Neck Cancer
Rosiglitazone in Treating Patients With Locoregionally Extensive or Metastatic Thyroid Cancer
RATIONALE: Drugs such as rosiglitazone may make tumor cells more sensitive to radioactive iodine. PURPOSE: This phase II trial is studying how well rosiglitazone works in treating patients with locoregionally extensive or…
- Trial name
- NCT00098852
- Testing
- rosiglitazone maleate
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- University of California, San Francisco
Differentiated Thyroid Cancer (DTC), Papillary Thyroid Microcarcinoma
Decision Aid Efficacy in Low Risk Thyroid Cancer
Low-risk thyroid cancer grows very slowly. More than 99% of patients with this cancer survive for at least 5 years. There are 3 main treatment options: remove the whole thyroid, remove just the part of the thyroid with the cancer…
- Conditions
- Differentiated Thyroid Cancer (DTC), Papillary Thyroid Microcarcinoma, Papillary Thyroid Carcinoma
- Trial name
- NCT07536412
- Testing
- Decision Aid
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- University of Maryland, Baltimore
Non-Small Cell Lung Cancer, Medullary Thyroid Cancer
A Study of Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRETTO-001)
This is an open-label, first-in-human study designed to evaluate the safety, tolerability, pharmacokinetics (PK) and preliminary anti-tumor activity of selpercatinib (also known as LOXO-292) administered orally to participants…
- Conditions
- Non-Small Cell Lung Cancer, Medullary Thyroid Cancer, Colon Cancer, Any Solid Tumor
- Trial name
- LIBRETTO-001 (NCT03157128)
- Testing
- LOXO-292
- Where
- 85 sites in United States, Australia and 14 more
- Volunteers
- 857 people
- Sponsor
- Eli Lilly and Company
Thyroid Cancer, Papillary, Hypothyroidism
Type 2 Deiodinase Gene Polymorphism and the Treatment of Hypothyroidism Caused by Thyroidectomy in Thyroid Cancer Patients.
This project analyzes the relationship between type 2 deiodinase gene polymorphism and the TSH inhibitory treatment efficacy in thyroid cancer patients with thyroidectomy, and explored the factors influencing TSH inhibitory…
- Trial name
- NCT05247476
- Testing
- L-T4, L-T4+T3 (thyroid tablet)
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Zhongshan Hospital Xiamen University
Thyroid Cancer, Surgery
Thyroxine Replacement Therapy After Lobectomy for Low-risk Papillary Thyroid Carcinoma
Papillary thyroid carcinoma (PTC) is the most common thyroid cancer and has a good prognosis.According to the 2015 American thyroid association (ATA) guidelines, no gross extrathyroidal extension and the number of pathological…
- Conditions
- Thyroid Cancer, Surgery, Recurrence
- Trial name
- NCT06087068
- Testing
- Thyroxine
- Where
- China
- Volunteers
- 140 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Papillary Thyroid Cancer
CT Detection of Metastatic Lymphadenopathy in Papillary Thyroid Cancer
Localized thyroid cancer is potentially curable. Before thyroid surgery, an ultrasound test is done to see if cancer has spread to the lymph nodes in the neck.
- Trial name
- NCT03359668
- Testing
- Use of IV contrast during head and neck CT
- Volunteers
- 47 people
- Sponsor
- University Health Network, Toronto
Thyroid, Papillary Thyroid Cancer
A Study of Online Follow-up in Patients With Papillary Thyroid Cancer
The randomized, actively controlled, non-inferiority trial is scheduled to begin in August 2024 and run through August 2026. Inclusion criteria: (1) has undergone microwave ablation of thyroid or thyroidectomy (including…
- Trial name
- NCT06800482
- Testing
- online outpatient follow-up
- Where
- China
- Volunteers
- 388 people, healthy volunteers welcome
- Sponsor
- West China Hospital
Thyroid Cancer
Targeted Alpha Therapy Using Astatine (At-211) Against Differentiated Thyroid Cancer
Single intravenous administration of TAH-1005 is performed in patients with differentiated thyroid cancer (papillary cancer, follicular cancer) who cannot obtain therapeutic effect with standard treatment or who have difficulty…
- Trial name
- NCT05275946
- Testing
- Targeted alpha therapy
- Where
- Japan
- Volunteers
- 11 people
- Sponsor
- Osaka University
Recurrent Thyroid Cancer, Stage IV Follicular Thyroid Cancer
Romidepsin in Treating Patients With Recurrent and/or Metastatic Thyroid Cancer That Has Not Responded to Radioactive Iodine
This phase II trial is studying how well romidepsin works in treating patients with recurrent and/or metastatic thyroid cancer that has not responded to radioactive iodine.
- Conditions
- Recurrent Thyroid Cancer, Stage IV Follicular Thyroid Cancer, Stage IV Papillary Thyroid Cancer
- Trial name
- NCT00098813
- Testing
- romidepsin, laboratory biomarker analysis, positron emission tomography
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- National Cancer Institute (NCI)